This retrospective investigation compared the efficacy and safety of bortezomib administration via subcutaneous and intravenous dosing in 307 patients with newly diagnosed multiple myeloma from a single Chinese center. Subcutaneous bortezomib is associated with better tolerance. However, intravenous administration achieves a faster and deeper response in these patients. Background: Peripheral neuropathy (PN) is an important toxicity that limits the use of bortezomib (Btz). Attempts to reduce PN have included its subcutaneous (SC) administration. Patients and Methods: We retrospectively analyzed 307 patients with newly diagnosed multiple myeloma from a single Chinese center, receiving Btz-based regimens administered either via SC injection (SC group, n ¼ 167) or intravenous (IV) infusion (IV group, n ¼ 140). The efficacy and safety of Btz administration via SC and IV were then compared. Results: Most baseline characteristics were similar between these 2 groups. A lower frequency of adverse events, especially grade ! 3 PN (P ¼ .002), was observed in the SC group compared with the IV group. The estimated median Btz dosage when PN developed was higher (20.8 mg/m 2 vs. 15.6 mg/m 2 ), and fewer patients reduced or discontinued Btz owing to adverse events in the SC group compared with the IV group. The overall response rate (! partial response [PR]) was comparable (94.8% vs. 96.2%). However, patients in the IV group required fewer cycles to achieve PR, whereas a larger proportion of patients in the IV group achieved ! very good PR. After a median follow-up of 23 months (range, 1-84 months), no significant difference in median progression-free survival (not arrived vs. 33.0 AE 2.735 months) and overall survival (not arrived vs. 56.0 months) was noted. Conclusion: SC Btz is associated with better tolerance; however, IV administration achieves a faster and deeper response in Chinese patients with newly-diagnosed multiple myeloma.
Introduction
Multiple myeloma (MM) is an incurable plasma cell malignancy primarily affecting the elderly. The variety of clinical signs and symptoms profoundly impact the lives of patients and imposes a heavy burden on society. However, recent basic and clinical research developments have led to the use of novel therapeutic agents, which have greatly improved overall survival (OS) and shifted treatment paradigms in MM.
The proteasome inhibitor bortezomib (Btz) is a potent agent used extensively in the treatment of both newly diagnosed and relapsed MM, and as part of induction, consolidation, conditioning, and maintenance therapies. [1] [2] [3] [4] [5] [6] [7] [8] The standard administration route for Btz is intravenous (IV), but IV administration poses a therapeutic challenge in patients who have poor venous access. IV Btz administration is also limited by Btz-induced peripheral neuropathy (BIPN), which significantly impacts patients' quality of life. 9 In 2008, a French group reported the results of a randomized phase I study (CAN-1004) that compared the pharmacokinetics and pharmacodynamics of IV versus subcutaneous (SC) administration of Btz in patients with relapsed or refractory MM (RRMM). This study also assessed the safety and efficacy of these 2 administration routes. The plasma concentration of Btz and the percent inhibition of 20S proteasome were measured on days 1 and 11 of cycle 1. Btz systemic exposure was equivalent with SC versus IV, which led to similar overall 20S inhibition in both arms. The safety profile and response rate of SC did not appear inferior to IV, and the local tolerance of SC injection was also good. Based on these exploratory findings, SC administration was deemed as a promising alternative to IV injection. 10 These outcomes were subsequently confirmed in the randomized, prospective MMY-3021 study involving patients with RRMM, [11] [12] [13] which led to the 2012 approval of SC Btz in the United States and European Union. However, despite several other reports supporting the use of SC Btz, 14, 15 there is very limited data available about the safety and efficacy profile of SC Btz in Chinese and Asian patients with newly diagnosed MM (NDMM). [16] [17] [18] [19] Few studies with small cohorts compared the 2 administration routes in Asian patients. 20, 21 Promising results from our preliminary studies showed that SC Btz significantly decreases and delays peripheral neuropathy (PN) in RRMM and particularly in NDMM, prompting this follow-on study to look at a larger cohort of patients with NDMM. We report, for the first time, that patients with IV Btz may have quicker and deeper response, especially in the Btz (also named as PS341) combined with adriamycin and dexamethasone (PAd) group compared with the SC group. This has significant relevance in practice. This is also the largest cohort of Asian patients and demonstrates the relevance of SC versus IV administration of Btz in this population.
Materials and Methods

Patients and Study Design
This retrospective, historical control study was conducted at a single center, and its design was approved by the Institutional Review Board of the Blood Diseases Hospital at Tianjin, China. Informed consent was obtained from all patients included in this study. Data from 307 patients with NDMM treated with a Btzbased regimen at the Lymphoma and Myeloma Center of this Blood Diseases Hospital between May 1, 2008, and December 31, 2014 was abstracted from the medical records and subsequently analyzed.
Patients were assigned to receive Btz-based regimens, including PAd or Btz combined with cyclophosphamide (CTX) and dexamethasone (BCd) (Btz 1.3 mg/m 2 on days 1, 4, 8 and 11; adriamycin 9 mg/m 2 intravenously on days 1-4; or CTX 500 mg/m 2 , orally on days 1, 8, 15 , and dexamethasone 20 mg/day, orally or intravenously on days 1, 2, 4, 5, 8, 9, 11, and 12). Btz was administered by either IV (historical control IV group) before Feb 28, 2012 or SC injection (SC group) after March 1, 2012. The IV injections were administered at a concentration of 1 mg/mL as a 3-to 5-second intravenous push, whereas SC injections were administered at 2.5 mg/mL to limit total volume. All treatments were repeated every 3 to 4 weeks. After at least 4 cycles of treatment, patients underwent consolidation therapy with either autologous stem cell transplant (if patient was < 65 years old and without contraindication to autologous stem cell transplant) combined with the original chemotherapy regimen or only the original chemotherapy regimen. After up to 9 cycles of induction and consolidation chemotherapy, patients were maintained with either thalidomide or lenalidomide, plus dexamethasone. Where necessary, patients also received supportive treatment with zoledronic acid every 1 to 2 months. All patients received prophylactic acyclovir.
Patients who completed ! 1 dose of Btz were included in this study, and the data on their demographic characteristics and disease profiles ( 
Assessment of Treatment Safety and Efficacy
Safety analysis was based on all patients who received ! 1 dose of Btz. Safety was monitored for 30 days after the last dose by grading the toxicities based on the National Cancer Institute's Common Toxicity Criteria (version 3.0). Toxicity-related therapeutic adjustments were recorded along with the dose at which PN was induced or aggravated. For IV patients, PN was managed using a dosemodification guideline developed based on experience in phase II studies. 9 As for SC patients, an updated stricter dose-modification guidelines was used. 23 Efficacy analysis was based on all patients who completed ! 1 cycle of the Btz-based regimen. In both groups, disease status was assessed after every cycle of induction and consolidation chemotherapy, and once every 3 months during maintenance therapy, in accordance with the International Myeloma Working Group's uniform response criteria for MM, incorporating near complete response (nCR). 24 Progression-free survival (PFS) is defined as the time from the start of the treatment to disease progression or death (regardless of cause), whichever comes first. Overall survival (OS) is defined as the time elapsed between treatment initiation and death. The efficacy and safety of Btz administration via SC and IV were then compared.
Statistical Considerations
The data are presented as median AE standard deviation (SD). Independent samples of nonparametric tests were used to compare the difference between the 2 groups. The Spearman association and 
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logarithmic regression analyses were performed. Survival was estimated according to the Kaplan-Meier method, and survival curves were compared using the log-rank test. Two-tailed tests were used, with P-value .05 indicating statistical significance. The SPSS 23.0 software package was used.
Results
Patients: Comparable Baseline Characteristics Between the IV and SC Groups
Among the total 307 patients enrolled in our study, 140 received IV Btz, whereas 167 received SC Btz. The summary of the baseline characteristics of all patients is listed in Table 1 . Overall patients from 22 Chinese provinces were diagnosed and treated at the same Lymphoma and Myeloma Center of the Blood Diseases Hospital, with the majority (92.8%) from 10 northern provinces of China. The median age of the cohort was 56 years (range, 25-77 years). Patient demographics and all other baseline characteristics (including age, M-protein type and quantity, percentage of plasma cells in BM and PB, ISS, R-ISS, risk group according to cytogenetics characteristics, PN and diabetes mellitus before treatment, etc.) were similar between the IV and SC groups. About 60.7% (85/140) of patients in the IV group and 61.1% (102/167) patients in the SC group received the PAd regimen, whereas the remaining patients in both groups received BCd (P ¼ .948).
Safety Profile: SC Btz has a Better Safety Profile and is Associated With Less Severe PN
Adverse events (AEs) associated with IV Btz and SC Btz are listed in Tables 2 and 3 . Patients who received IV Btz had more frequent grade ! 3 AEs compared with those who received SC Btz. PN remained one of the most common and important Btzrelated AEs that greatly affects patients' quality of life. Although the overall incidence of PN was only slightly lower in patients receiving SC Btz than those receiving IV Btz (49.7% vs. 57.1%; P ¼ .154), the frequency of grade ! 3 PN was significantly less in the SC group (8.4% grade 3 vs. none grade ! 4) compared with the IV group (20.7% grade 3 vs. 2.1% grade 4; P ¼ .002). Importantly, the median dosage of Btz associated with PN development was higher in the SC group (Table 2, Figure 1) . Compared with the risk of PN development in the IV group, the risk in the SC group is 0.561 (95% confidence interval, 0.411-0.765). When compared with the risk of grade ! 2 PN development in the IV group, the risk in the SC group is only 0.349 (95% confidence interval, 0.217-0.559). Subgroup analysis according to the regimen used (PAd or BCd) showed that patients tolerated significantly higher doses to develop/worse PN when Btz was administered as SC versus IV, independent of whether doxorubicin or cyclophosphamide was used. In patients with PN who received long-term follow-up, the resolution rate was not significantly different between the SC and IV groups. A total of 68.1% and 77.3% patients in the SC and IV groups, respectively, showed improvement to a lower grade of PN, or even complete resolution (P ¼ .215). However, the median time to improvement was shorter in the SC versus the IV group (5 vs. 7.5 months, respectively; P < .001). This was observed both in patients receiving PAd (5 vs. 10 months, respectively; P < .001) or BCd (4.5 vs. 6.5 months, respectively; P ¼ .028). There were also fewer patients who developed ! grade 3 fatigue, paralytic ileus, and constipation in the SC group. These AEs may also be related to the neuropathic toxicity of Btz (Table 3) . Additionally, there were significantly fewer ! grade 3 hematologic toxicities (ie, leukopenia, anemia, thrombocytopenia) and infections in the SC group (Table 3) . Notably, 11 (6.6%) of 167 patients had ! 1 SC injection site reaction reported as an AE that, however, did not require dose-adjustment. Based on these observations, SC Btz was found to have a better safety profile, especially with regards to PN.
Btz Dosing: Patients in the SC Group Received a Higher Dose of Btz
One hundred forty individuals in the IV group completed 466.5 cycles of Btz-based chemotherapy, with a median of 3 cycles/patient (range, 0.5-9 cycles/patient), whereas 167 patients in the SC group completed 684.5 cycles of Btz-based chemotherapy with a median At a median follow-up of 18.5 months (range, 1-41 months) in the SC group, and 41 months (range, 1-84 months) in the IV group, the median PFS and OS were similar between the 2 groups (PFS: not arrived vs. 33.0 AE 2.7 months, respectively; P ¼ .976; and OS: not arrived vs. 56.0 months, respectively; P ¼ .425) (Figure 2 ). The median number of cycles to initial response was 1 (range, 1-4 cycles) in both the IV and SC groups (P ¼ .396). The majority of patients in both groups (92.3% in the IV group and 82.5% in the SC group) achieved ! minimal response (MR) after only 1 cycle of Btz-based therapy. However, the depth of the initial response between these 2 groups was significantly different (P ¼ .001) with better response in the IV versus the SC group after 1 cycle of chemotherapy (77.7% ! PR, with 22.3% ! VGPR in IV Btz vs. 61.7% ! PR, with 13.0% ! VGPR in SC Btz). MR was achieved by 14.6% of the patients in the IV group and 20.8% in the SC group (Table 5 ). The ORR (! PR) was similar between the 2 groups (96.2% vs. 94.8%); however, VGPR or higher response was achieved more frequently with IV Btz versus SC Btz (75.0% vs. 63.2% respectively; P ¼ .014) ( Table 5 ). 25 and was also corroborated in the later phases of clinical studies. 9, 26, 27 Multiple interventions have been (and are being) investigated in a bid to decrease the incidence and severity of BIPN. The administration of Btz via the SC route was one such intervention, which was reported to be associated with a lower incidence of BIPN in a phase III study comparing IV versus SC Btz. 11, 13 In this context, our study is the first comparison of IV versus SC Btz in Chinese patients with NDMM. Our analysis confirmed that Btz administration via SC offers a comparable efficacy (ORR and survival), with the added advantage of an improved safety profile consistent with earlier reports (CAN-1004 and MMY-3021 trials for RRMM, German-Speaking Myeloma Multicenter Group (GMMG)-MM5 trial for NDMM). 10, 13, 28 Patients in our SC group tolerated Btz better than those in the IV group. SC Btz was associated with lower incidence and severity of PN, consistent with the reported findings from MMY-3021 and GMMG-MM5. It is of note that we followed the updated stricter dose-modification guidelines for Btz-related neuropathic pain and/or peripheral sensory or motor neuropathy 23 in the SC group. Importantly, fewer patients in the SC group discontinued Btz because of AEs, especially because of PN, which allowed these patients to receive more cycles of chemotherapy and a higher total dosage of Btz. Regrettably, one of the main reasons for discontinuing Btz was the financial hardship brought about by the high cost of Btz coupled with the denial of medical insurance coverage in China. As a result, both the median number of cycles and total dose of Btz are lower in our study when compared with other published reports. Notably, one other retrospective study 14 reported that SC Btz induces similar therapeutic response rates as intravenous Btz in MM without the reduction in incidence of PN. However, this study used once-weekly Btz, and subgroup analysis revealed a higher percentage of patients had preexisting neuropathy in the SC versus the IV arm (18% in SC arm vs. 13% in IV arm; P ¼ .073). In addition, the incidence and severity of non-PN AEs (especially hematologic AEs) are also lower in our SC cohort versus the IV cohort. In our study, the incidence of ! grade 3 infection is much higher in the IV group than in the SC group. This phenomenon is in accordance with the significant higher incidence of ! grade 3 leukopenia in the IV group, which is the highrisk factor for severe infection. In our analysis, IV Btz, on the other hand, has the advantage of bringing about quicker and deeper response compared with SC administration. After 1 cycle of chemotherapy, more patients achieved ! PR in the IV group than the SC group. Even though the median number of cycles to initial response was 1 in both groups, the depth of initial response was better in the IV versus the SC group. As for the best response across all cycles, a greater percentage of patients in the IV group achieved ! VGPR, even though median 1 more cycle of Btz-based chemotherapy was administrated in the SC group compared with the IV group. The MMY-3021 trial also reported a median time to initial response of 1.4 months in both groups (SC and IV) in patients with RRMM; however, they did not illustrate the detailed depth of the initial response. 11 In the GMMG-MM5 trial, subgroup analysis revealed that patients with baseline creatinine ! 2 mg/dL who were treated with IV BCd had much higher rates of nCR/CR (47% in the IV group vs. 11% in the SC group; P ¼ .03), whereas patients with adverse cytogenetic abnormalities who were treated with IV PAD had much higher ! VGPR rates than those treated with SC Btz (45% in the IV group vs. 29% in the SC group; P ¼ .05). Similar phenomena were also noticed in the whole BCD arm (! VGPR, 42% in the IV group vs. 29% in the SC group; P ¼ .02; nCR/CR, 27% in the IV group vs. 14% in the SC group; P ¼ .01). 28 Previous pharmacokinetic and pharmacodynamic studies have documented that IV administration of Btz has a higher C max (the maximum serum concentration) and a shorter T max (the time after administration of a drug when the maximum plasma concentration is reached) compared with SC administration. 13 These 2 pharmacokinetic factors seem to have an impact on time to response and may partly explain the deeper response observed in our IV group. The comparable ORR could be owing to the overall equivalent systemic exposure of Btz between the SC and IV groups. 10, 11 This study raises interesting question about possible pharmacokinetic differences in the Chinese population. We plan to study this in the future. Importantly, it also brings about a point that IV administration may have a quicker effect, which may have clinical significance especially in newly-diagnosed patients and patients with renal dysfunction or aggressive disease where a quicker response may be advantageous, whereas for patients with indolent diseases, SC Btz can achieve a better balance between efficacy and toxicity. This phenomenon also provides us the possibility of administering Btz by IV first to rapid control disease, then following with SC administration to get better tolerance. We have observed a higher ORR in our study compared with other studies comparing IV versus SC Btz mainly because, unlike 
Subcutaneous Bortezomib in Multiple Myeloma
other studies, we studied patients with NDMM who received 3-drug regimens as initial therapy. Similar responses have been reported with other 3-drug regimens such PAd, BCd, VRd, and BCd-modified in NDMM (88%-100%). [4] [5] [6] 15, [29] [30] [31] There are some limitations to this study. First, this study is not a prospective randomized controlled trial. Second, Btz was not administrated during the same period in the IV and SC groups. Third, the subgroup analyses lack power as the cohort size is not sufficiently large, especially for the different cytogenetic subgroups. Lastly, the differences in pharmacokinetics and pharmacodynamics between SC and IV administration of Btz in Chinese patients was not studied, which represents a missed opportunity as race or ethnicity is known to play a key role in inter-patient variability in drug response. 32 Thus, a randomized controlled trial with a larger cohort of enrolled patients and longer follow-up times will be required to conclusively address these issues in the future.
Conclusion
In conclusion, we report that, compared with IV administration, SC administration of Btz, when combined with adriamycin or cyclophosphamide, results in significantly reduced toxicity and similar ORR, PFS, and OS. Thus, SC administration is an acceptable alternative for Chinese patients with NDMM owing to its superior safety profile and similar ORR and survival. However, IV administration of Btz leads to more rapid and deeper responses in these patients. This study raises the point that SC Btz can provide better balance between efficacy and toxicity, especially for patients with indolent diseases, whereas IV Btz may control tumor load more rapidly, which may be preferred in patients with more aggressive diseases or renal failure.
Clinical Practice Points
The use of Btz has greatly improved OS and shifted treatment paradigms in MM, but PN is an important toxicity. Attempts to reduce PN have included SC administration. We retrospectively compared the efficacy and safety of Btz administration via SC and IV in 307 patients with NDMM from a single Chinese center. We found that the estimated median Btz dosage when PN developed was higher (20.8 mg/m 2 vs. 15.6 mg/m 2 ) and fewer patients reduced or discontinued Btz owing to AEs in the SC group compared with the IV group. The ORR (! PR) and survival (PFS and OS) were comparable between these 2 groups. Patients in the IV group required fewer cycles to achieve PR, and a larger proportion of patients in the IV group achieved ! VGPR, although a higher total Btz dosage was used in the SC group. We report, for the first time, that SC Btz is associated with better tolerance, whereas quicker and deeper responses can be achieved by IV Btz in Chinese patients with NDMM.
